| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C4orf35 |
| Uniprot No | Q96KC9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-395aa |
| 氨基酸序列 | MAEDGLPKIYSHPPTESSKTPTAATIFFGADNAIPKSETTITSEGDHVTSVNEYMLESDFSTTTDNKLTAKKEKLKSEDDMGTDFIKSTTHLQKEITSLTGTTNSITRDSITEHFMPVKIGNISSPVTTVSLIDFSTDIAKEDILLATIDTGDAEISITSEVSGTLKDSSAGVADAPAFPRKKDEADMSNYNSSIKSNVPADEAVQVTDSIIPEAEIPPAPEESFTTIPDITALEEEKITEIDLSVLEDDTSAVATLTDSDEKFITVFELTTSAEKDKDKREDTLLTDEETTEGASIGMERDTANEAETHSVLLTAVESRYDFVVPASIATNLVEESSTEEDLSETDNTETVPKITEPFSGTTSVLDTPDYKEDTSTTETDIFELLKEEPDEFMI |
| 分子量 | 69.3 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人C4orf35蛋白的3篇代表性文献概述（注：文献信息为模拟示例，仅供参考）：
---
1. **文献名称**：*"Functional characterization of recombinant human C4orf35 protein in DNA damage response"*
**作者**：Chen L. et al. (2021)
**摘要内容**：本研究通过在大肠杆菌系统中表达并纯化重组人C4orf35蛋白，发现其能够结合单链DNA并在体外增强Rad51介导的同源重组修复活性，提示其在DNA损伤修复中的潜在作用。
2. **文献名称**：*"C4orf35 interacts with mitochondrial proteins and regulates oxidative stress pathways"*
**作者**：Wang Y. et al. (2019)
**摘要内容**：利用重组C4orf35蛋白进行免疫共沉淀-质谱分析，鉴定其与线粒体复合物I的相互作用，实验表明C4orf35敲低导致细胞内活性氧（ROS）积累，表明其在氧化应激调控中的功能。
3. **文献名称**：*"C4orf35 as a novel biomarker: High expression correlates with poor prognosis in hepatocellular carcinoma"*
**作者**：Tanaka K. et al. (2020)
**摘要内容**：通过重组蛋白制备抗体，在肝癌组织中检测到C4orf35显著高表达，且其过表达通过激活PI3K/AKT通路促进肿瘤细胞侵袭，提示其作为治疗靶点的潜力。
---
（注：以上内容为示例性模拟，实际文献需通过学术数据库检索确认。）
The human C4orf35 protein, encoded by the chromosome 4 open reading frame 35 gene, remains poorly characterized in current scientific literature. This gene is evolutionarily conserved across vertebrates, suggesting a potential role in fundamental cellular processes. The protein is predicted to contain 235 amino acids with a molecular weight of approximately 27 kDa, featuring a conserved domain of unknown function (DUF4803) spanning residues 24-188. Structural predictions indicate possible α-helical and disordered regions, though experimental validation is lacking. C4orf35 shows ubiquitous but variable expression across human tissues, with higher mRNA levels observed in reproductive organs and the gastrointestinal system. Early studies suggest possible involvement in DNA repair pathways through weak associations with poly(ADP-ribose) polymerase 1 (PARP1), though this requires confirmation. Its localization appears primarily nuclear, with some evidence of nucleolar enrichment. Several cancer genomics databases note altered C4orf35 expression patterns in malignancies, including prostate and breast cancers, though the biological significance remains unclear. Current research challenges include establishing its precise molecular interactions, post-translational modifications, and disease relevance. The "recombinant" designation typically refers to experimentally engineered versions used in functional studies, as native purification remains technically difficult due to low natural abundance. Further characterization of this protein could provide insights into basic cell biology and potential therapeutic targets.
×
